Outcomes of eyes with lesions composed of >50% blood in the comparison of age-related macular degeneration treatments trials (CATT)

Michael M. Altaweel, Ebenezer Daniel, Daniel F. Martin, Robert A. Mittra, Juan E. Grunwald, Michael M. Lai, Alexander Melamud, Lawrence S Morse, Jiayan Huang, Frederick L. Ferris, Stuart L. Fine, Maureen G. Maguire

Research output: Contribution to journalArticlepeer-review

29 Scopus citations

Abstract

Objective To compare baseline characteristics, treatment frequency, visual acuity (VA), and morphologic outcomes of eyes with >50% of the lesion composed of blood (B50 group) versus all other eyes (Other group) enrolled in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Design Prospective cohort study within a multicenter randomized clinical trial. Participants CATT patients with neovascular age-related macular degeneration (AMD). Methods Treatment for the study eye was assigned randomly to either ranibizumab or bevacizumab and to 3 different dosing regimens over a 2-year period. Reading center graders evaluated baseline and follow-up morphology in color fundus photographs, fluorescein angiography (FA), and optical coherence tomography (OCT). Masked examiners tested VA. Main Outcome Measures Morphologic features and VA at 1 and 2 years. Results The B50 group consisted of 84 of 1185 (7.1%) patients enrolled in CATT. Baseline lesion characteristics differed between groups. In the B50 group, choroidal neovascularization size was smaller (0.73 vs 1.83 disc areas [DA]; P < 0.001), total lesion size was greater (4.55 vs 2.31 DA; P <0.001), total retinal thickness was greater (524 vs 455 μm; P = 0.02), and mean VA was worse (56.0 vs 60.9 letters; P = 0.002). Increases in mean VA were similar in the B50 and Other groups at 1 year (+9.3 vs +7.2 letters; P = 0.22) and at 2 years (9.0 vs 6.1 letters; P = 0.17). Eyes treated PRN received a similar number of injections in the 2 groups (12.2 vs 13.4; P = 0.27). Mean lesion size in the B50 group decreased by 1.2 DA at both 1 and 2 years (primarily owing to resolution of hemorrhage) and increased in the Other group by 0.33 DA at 1 year and 0.91 DA at 2 years (P < 0.001). Leakage on FA and fluid on OCT were similar between groups at 1 and 2 years. Conclusions In CATT, the B50 group had a visual prognosis similar to the Other group. Lesion size decreased markedly through 2 years. Eyes like those enrolled in CATT with neovascular AMD lesions composed of >50% blood can be managed similarly to those with less or no blood.

Original languageEnglish (US)
Pages (from-to)391-398.e5
JournalOphthalmology
Volume122
Issue number2
DOIs
StatePublished - Feb 1 2015

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'Outcomes of eyes with lesions composed of >50% blood in the comparison of age-related macular degeneration treatments trials (CATT)'. Together they form a unique fingerprint.

Cite this